Cancer

Lisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor Events

BASKING RIDGE, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage…

1 year ago

Nusano Adds to Executive Leadership Team in Advance of 2025 Commercialization

VALENCIA, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Nusano, Inc., a physics company transforming the production of medical radioisotopes, today…

1 year ago

Cancer centers launch Cancer AI Alliance to unlock discoveries, transform care using cancer data and applied AI

AWS, Deloitte, Microsoft and NVIDIA bring the latest in AI technology, coordination, and compute to the alliance and back with…

1 year ago

Rice’s Biotech Launch Pad to lead commercialization of bioelectrical implant treatment for obesity, type 2 diabetes

$34.9M ARPA-H project aims to disrupt therapies' market and radically improve treatment options HOUSTON, Oct. 2, 2024 /PRNewswire/ -- Rice…

1 year ago

Gut Microbiome Health Tech Innovator, Ixcela Launches Virtual Clinic to Ease Cancer Symptoms After Landmark Roper St. Francis Healthcare Pilot

Gut Microbiome Health Plays Critical Role Reducing Cancer Care Side Effects including Fatigue, Brain Fog, Nausea, Constipation, Sleep and Overall…

1 year ago

The Caris Precision Oncology Alliance Welcomes UVA Cancer Center

UVA Cancer Center joins the extensive network of leading cancer institutions committed to improving patient outcomes through innovations in precision…

1 year ago

Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments

ATLANTA, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet…

1 year ago

PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation

100% 36-month overall survival (OS) and progression-free survival (PFS) rates in patients fully treated with Versamune® HPV combined with chemoradiation (N=8)88%…

1 year ago

Rudolph E. Tanzi, Co-Director of MassGeneral Institute for Neurodegenerative Disease, Chairs Cognos Neurodegenerative Scientific and Clinical Advisory Board

INGLEWOOD, California, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Cognos Therapeutics, a private hi-tech medical technology company focused on the development…

1 year ago

Verrica Pharmaceuticals Announces Restructuring of Commercial Organization

- Company significantly reduces cost structure with a realigned sales, marketing and operational infrastructure - Sales and marketing efforts to…

1 year ago